J&J Positions Tremfya as Stelara Successor with Strong Head-to-Head Data

Johnson & Johnson on Tuesday unveiled early Phase II/III data from its GALAXI 2 and GLAXI 3 studies, showing that its IL-23 blocker Tremfya (guselkumab) outperformed its blockbuster antibody Stelara (ustekinumab) in the treatment of moderately to severely active Crohn’s disease.